Key facts
- TIRmed Pharma’s last known valuation is $3.0M (Jan 2023).
- It has raised $6.7M; the latest was Later Stage VC ($4.7M) in Apr 2025.
- Notable investors include European Union, Almi Invest, Nolsterby Invest, SU Holding, SWElife — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for TIRmed Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for TIRmed Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TIRmed Pharma
Developer of a non-steroid treatment of eczema designed to dampen inflammation and relieve itching caused due to innate immune responses. The company offers chemically stabilized single-stranded oligonucleotide formulated in a cream form, enabling atopic dermatitis patients with self-applied and easy-to-use at-home anti-itch treatment.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2018
- Employees
- 6
- Website
- tirmedpharma.com/
- Ownership
- Privately Held (backing)
TIRmed Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TIRmed Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TIRmed Pharma in its N-PORT filings yet. We sweep new filings monthly.